Current Report Filing (8-k)
April 09 2021 - 4:10PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 8, 2021
Qualigen
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37428
|
|
26-3474527
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
2042
Corte Del Nogal, Carlsbad, California 92011
(Address
of principal executive offices) (Zip Code)
(760)
918-9165
(Registrant’s
telephone number, including area code)
n/a
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $.001 per share
|
|
QLGN
|
|
The
Nasdaq Capital Market of The Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this
chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act [ ]
Item
8.01 Other Events.
Qualigen
Therapeutics, Inc., a biotechnology company primarily focused on developing novel therapeutics for the treatment of cancer and infectious
diseases, announces that it has withdrawn the Emergency Use Authorization application which it had submitted to the US Food and Drug
Administration in June 2020 for its FastPack® SARS-CoV-2 IgG diagnostic test for COVID-19 antibodies. During the nine months during
which the emergency application was with the FDA, alternative tests and testing practices have taken hold and we believe there is no
longer a viable business case for scale-up of the test.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
QUALIGEN
THERAPEUTICS, INC.
|
|
|
|
Date:
April 9, 2021
|
By:
|
/s/
Michael S. Poirier
|
|
|
Michael
S. Poirier, President and Chief Executive Officer
|
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Sep 2023 to Sep 2024